Clinical Trial Update: Recombinant Human IL-7 (NT-I7) in Relapsed/Refractory Multiple Myeloma Following BCMA CAR-T Therapy (Cilta-cel) [Phase 1]

View source ↗

Summary

Phase 1 study evaluating NT-I7 (recombinant human interleukin-7) in relapsed/refractory multiple myeloma patients who previously received BCMA CAR-T therapy wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• NT-I7

Snippet

Sponsor: Washington University School of Medicine | Conditions: Multiple Myeloma, Multiple Myeloma in Relapse | Phase 1 | Status: NOT_YET_RECRUITING